Lonza

Lonza Group is a Swiss global pharmaceutical, biotechnology, and nutrition manufacturing corporation based in Basel, with main operations in Europe, North America, and South Asia. Lonza was founded in Switzerland in the late nineteenth century. The company offers product development services to the pharmaceutical and biologic sectors, including bespoke manufacture of biopharmaceuticals and detection systems, as well as bioscience-related services.

Lonza collaborates with various pharmaceutical companies to manufacture biologics. In 2009, Lonza collaborated with Teva to research and produce biosimilars. They signed an agreement with GlaxoSmithKline in 2010 to develop therapeutic monoclonal antibodies. Lonza signed an agreement with Bristol-Myers Squibb in 2014 to produce two biologic pharmaceuticals. Imbruvica for Pharmacyclics and Mydicar for Celladon are both manufactured by Lonza. Lonza signed a contract with Alexion in 2015 to build a new facility specialized to Alexion manufacture. Lonza and Sanofi collaborated in 2017 to build a new biologics manufacturing plant.

Moderna signed a manufacturing agreement with Lonza in May 2020 to produce its (mRNA-1273) COVID-19 vaccine active ingredient, with sterile production and fill-finish activities growing to 500 million doses beginning in 2021. The mRNA bulk vaccination production began in January 2021, shortly after Swiss Federal Councilor Alain Berset's official visit. Lonza Group is responsible for the global manufacture of two-thirds of the raw materials for the Moderna vaccine at facilities in the United States and Switzerland. In addition, the company has begun working with Altimmune Inc. to develop a nasal COVID-19 vaccine.

Founded: 1897

Headquarters: Basel, Switzerland

Website: https://www.lonza.com/